Drug updated on 5/17/2024
Dosage Form | Capsule (oral; 200 mg) |
Drug Class | Hedgehog pathway inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Sonidegib (Odomzo) is used for treating adult patients with locally advanced basal cell carcinoma (BCC) that has recurred after surgery or radiation therapy, or for those who are not candidates for surgery or radiation therapy.
- Two studies were analyzed to gather information about this medication.
- These studies compared sonidegib with vismodegib, both are sonic hedgehog inhibitors used in treating BCC and metastatic BCC, as well as medulloblastoma. Safety profiles showed common adverse effects such as muscle spasms, dysgeusia, alopecia, but sonidegib users reported more nausea and diarrhea, whereas vismodegib users experienced more weight loss.
- In treating BCC, the overall response rate was 50.1% for sonidegib versus 68.5% for vismodegib; despite the difference, both medications are considered effective, but high discontinuation rates suggest the importance of managing expectations.
- For SHH-driven medulloblastoma treatment, sonidegib had a significantly higher overall response rate than vismodegib, particularly among pediatric patients where its efficacy was found to be 3.67 times higher than that of vismodegib's.
- Efficacy and safety evaluations for both adults with BCC and children/adults with SHH-driven medulloblastoma highlighted sonidegib's increased efficacy in pediatric patients, suggesting it could be a preferred option for treating this subgroup due to its targeted therapeutic potential against their specific cancer type.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Odomzo (sonidegib) Prescribing Information. | 2023 | Sun Pharmaceutical Industries, Inc., Cranbury, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: an updated systematic review and meta-analysis (2009-2022). | 2023 | American Journal of Clinical Dermatology |
Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. | 2019 | Acta Neuropathologica Communications |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. | 2019 | European Journal of Cancer |